articleAntimicrobial Agents and ChemotherapyJan 10, 2022HYBRID OA

Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed

MSMark S. ButlerVGValeria GiganteHSHatim SatiSPSarah PaulinLALaila Al-Sulaiman

The University of Queensland · The University of Texas Health Science Center at Houston · +16 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

There is an urgent global need for new strategies and drugs to control and treat multidrug-resistant bacterial infections. In 2017, the World Health Organization (WHO) released a list of 12 antibiotic-resistant priority pathogens and began to critically analyze the antibacterial clinical pipeline. This review analyzes "traditional" and "nontraditional" antibacterial agents and modulators in clinical development current on 30 June 2021 with activity against the WHO priority pathogens mycobacteria and Clostridioides difficile. Since 2017, 12 new antibacterial drugs have been approved globally, but only vaborbactam belongs to a new antibacterial class. Also innovative is the cephalosporin derivative cefiderocol,…

Citation impact

237
total citations
FWCI
22.18
Percentile
100%
References
66
Citations per year

Authors

19
  • MS
    Mark S. ButlerCorresponding

    The University of Queensland

  • VG
    Valeria Gigante
  • HS
    Hatim Sati
  • SP
    Sarah Paulin
  • LA
    Laila Al-Sulaiman

Topics & keywords

Topics
Keywords
  • Antibacterial agent
  • Antibiotics
  • Antibacterial activity
  • Clinical trial
  • Antibacterial peptide
  • Cephalosporin
No related works found for this paper.

Funding